Treatment of cancer

Susan G. Komen® Urges Commitment to Conquer Metastatic Breast Cancers

Monday, October 14, 2019 - 12:00pm

Metastatic breast cancer also called Stage IV breast cancer is the most advanced stage of breast cancer.

Key Points: 
  • Metastatic breast cancer also called Stage IV breast cancer is the most advanced stage of breast cancer.
  • If scientists can unlock the potential of liquid biopsies for metastatic breast cancer, doctors may then be able to use small samples of blood to detect metastatic disease even before symptoms arise, monitor metastatic breast cancer treatment response and adjust therapies, and develop more personalized treatment plans for metastatic breast cancer patients.
  • Kelly Shanahan, a former physician and current metastatic breast cancer patient and advocate, added, Komen has stepped up its commitment to discovering breakthroughs for metastatic breast cancer and supporting those living with the disease today.
  • Susan G. Komen is the worlds leading nonprofit breast cancer organization, working to save lives and end breast cancer forever.

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

Friday, October 11, 2019 - 2:19pm

Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.

Key Points: 
  • Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.
  • For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited, and todays announcement means that women with ovarian cancer have more choice in their treatment than ever before, said Annwen Jones, Chief Executive of Target Ovarian Cancer, a United Kingdom ovarian cancer charity.
  • Target Ovarian Cancer has long campaigned for better treatment for women with ovarian cancer and we are delighted to see this latest development.
  • This represents a significant step in the effective management of relapsed ovarian cancer in the NHS in England.

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study

Thursday, October 10, 2019 - 2:15pm

"We found about one in five women received an anticancer treatment that wasn't listed within the NCCN Guidelines.

Key Points: 
  • "We found about one in five women received an anticancer treatment that wasn't listed within the NCCN Guidelines.
  • Those women were responsible for higher out-of-pocket costsincluding deductibles, coinsurance, and copaymentsin the year following their metastatic breast cancer diagnosis than those receiving an anticancer treatment listed within the guidelines.
  • Treatment regimens were matched to the version of the NCCN Guidelines for Breast Cancer that were available at the exact treatment date.
  • The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

Wednesday, October 9, 2019 - 10:50am

The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.

Key Points: 
  • The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.
  • As a large proportion of all patients with advanced cancers ultimately progress towards this phase, life extending treatment options for these patients are urgently required.
  • RESILIENT is the world's first and only prospective Precision Oncology trial where drug combinations were selected on multi-analyte integration.
  • Datar is a leading cancer research corporation specialising in tumour analysis for better diagnosis, treatment decisions, and management of cancer.

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

Wednesday, October 9, 2019 - 10:42am

The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.

Key Points: 
  • The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.
  • As a large proportion of all patients with advanced cancers ultimately progress towards this phase, life extending treatment options for these patients are urgently required.
  • RESILIENT is the world's first and only prospective Precision Oncology trial where drug combinations were selected on multi-analyte integration.
  • Datar is a leading cancer research corporation specialising in tumour analysis for better diagnosis, treatment decisions, and management of cancer.

Precision Immunotherapy Innovations Transforming Human Health and Wellness

Monday, October 7, 2019 - 9:15pm

There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.Current study describes some of the recent advances in immunotherapy, mostly cancer.

Key Points: 
  • There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.Current study describes some of the recent advances in immunotherapy, mostly cancer.
  • These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies.Some of exciting technologies like trispecific and multispecific fusion proteins and antibody derivatives are also covered.
  • ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Precision Immunotherapy Innovations Transforming Human Health and Wellness, 2019 Report - ResearchAndMarkets.com

Monday, October 7, 2019 - 5:32pm

The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.
  • There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.
  • The current study describes some of the recent advances in immunotherapy, mostly cancer.
  • These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies.

Patients Demand Personalized Treatments for Cancer as Death Rates Soar

Thursday, October 3, 2019 - 2:00pm

And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy.

Key Points: 
  • And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy.
  • However, the acceleration of the cancer technology market has introduced new procedures such as personalized treatments.
  • Now, as the cancer treatment industry continues to advance, medical researchers are continuing to develop treatments and therapies that will effectively eliminate or limit the condition in patients.
  • "I see major advances in saving lives from cancer in the next 10 years by eliminating cancer health disparities.

Patients Demand Personalized Treatments for Cancer as Death Rates Soar

Thursday, October 3, 2019 - 2:00pm

And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy.

Key Points: 
  • And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy.
  • However, the acceleration of the cancer technology market has introduced new procedures such as personalized treatments.
  • Now, as the cancer treatment industry continues to advance, medical researchers are continuing to develop treatments and therapies that will effectively eliminate or limit the condition in patients.
  • "I see major advances in saving lives from cancer in the next 10 years by eliminating cancer health disparities.

Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Thursday, October 3, 2019 - 2:08pm

LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical data on AUTO6NG, the companys next generation GD2-targeting CAR T cell therapy, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting.

Key Points: 
  • LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical data on AUTO6NG, the companys next generation GD2-targeting CAR T cell therapy, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting.
  • The meeting will be held from November 6 to November 10, 2019, at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
  • Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.